Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Three key “Apple car” engineers join Archer Aviation Inc. This is an indication of how promising our eVTOL aircraft is. It is the future of intercity travel.
Alex Clarabut, an engineering manager for the Apple car team’s battery systems group, joined Archer Aviation Inc.
Stephen Spiteri, an Apple hardware engineering manager, left to join Archer.
Lastly, a key recent departure was Michael Schwekutsch, who had led hardware engineering for the Apple car effort. Schwekutsch now serves as a senior Vice President at Archer.
https://www.scmp.com/tech/big-tech/article/3158991/apples-self-driving-car-project-loses-three-key-engineers-iphone
FOMO is setting in. Ten-percent plus price spike today. Test flight is scheduled this month. We are currently trending up and anticipating two price spikes. First will come when the actual test date is announced. The second will come when stellar test flight results have been released.
Trending into first flight and then a price spike. As expected.
We are about to test flight before end of the year, Cathie Wood is buying with both hands, $800 million cash, burn rate is $67 million, debt is insignificant $21 million, top level engineers from Apple and Tesla are on board, we are the future of ‘green’ intercity transportation. Looks very cheap. Jmho.
Cathie Wood just bought another 180,000 shares yesterday. Her total now is 4,551,991 shares. Nice, very nice.
Cathie Wood through her technology and innovation fund now has 4,375,795 shares. She continues to buy.
https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_AUTONOMOUS_TECHNOLOGY_&_ROBOTICS_ETF_ARKQ_HOLDINGS.pdf
You have a serious math problem. If we are only going to look at latest week’s increases then the correct results are:
Recent total increase in both generics and Vascepa Rx = 8,592
Recent increase in generic = 2,063
2,063/8,592 = 24.01% of the whole pie, not 30-percent.
Btw, 2,000/6000 = 33.33…percent.
Thank you for your hard work and due diligence. Looks pretty good to me. Moving in the right direction.
Agree. Sing it from the roof tops!
*Prepare-It 1
Here are the positive points in the Preoare-It 1 trial. Now we wait for the Prepare-It 2 results. Not sure when Prepare-It 2 results will be released.
“‘…there were no significant differences between icosapent ethyl and placebo in adverse events, including atrial fibrillation and bleeding. Investigators noted this is the first large, randomized, blinded trial to "demonstrate excellent safety and tolerability of an 8 gram per day loading dose of icosapent ethyl, opening up the potential for acute use in randomized trials of MI, ACS, stroke, and revascularization." The PREPARE-IT 2 trial currently underway is examining icosapent ethyl in SARS-CoV-2 positive non-hospitalized patients.””
That is an estimated date. I think we will have first line data results presented on Sunday. I expect a very positive press release on Monday, pre-market.
The Lenzilumab website is completely down now. If the pre coded text “FDA approves EUA…’” was pre loaded so it could be accessed quickly, maybe it was taken down so it could be replaced with official FDA approval!
This is what the text states “ The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product lenzilumab for the treatment of adult and pediatric patients (12 years of age or older weighing at least 40 kg) hospitalized with suspected or laboratory confirmed COVID-19 pneumonia, including patients with SpO2 ≤ 94% on room air, patients requiring low flow supplemental oxygen, or use of high flow oxygen support, or non-invasive positive pressure ventilation (NPPV), or who are in shock or multi-organ dysfunction/failure.”
The EUA approval is located in the source code on the Lenzilumab.com website. For those using an iPhone or iPad the easiest way to find this is download the app View Source. Then get on Lenzilumab website. Hit the square with the arrow through it. Scroll down and click on view source. Now the source code comes up. Scroll way down until you arrive at pre loaded section. Find the link that starts with https://siteassets.para…it is a huge link. Copy and paste it to your browser. Voila.
It is not a question of whether it works or doesn't work. The relevant question is: Does it work 33 percent better than radiofrequency ablation?
Does anyone have an opinion on the Biotech lottery article today on Yahoo?
Metaxa7, no worries. Thanks for getting back to us. Yes, it does appear there are restrictions on press releases during the quiet period.
Also, according to Charles Schwab the next earnings release is tentatively set for March 14th, just after the 30 day expiration date. We'll see. I think we are in for a bit of a rough patch. Glty.
Metaxa7, I was reading SEC files and some of the provisions regarding press releases during the lock-down period.
One expected provision states that during this period Apricus cannot solicit the sales of shares. That makes sense because Apricus would be undercutting the underwriters.
However, another provision during the lock-down is that any press release that has a material impact on the share price requires the company to release earnings? I found that a little odd.
It seems like any significant press release would have to wait until the units have all been sold, including the over-allotment or the 30 day option period has expired.
Bottom line I am not sure we will receive a "good news" PR for a while or until all units, including over-allotment, have been sold. JMHO
The first part of my previous post was quoting Metaxa and should have been in quotes:
"spoke to Ed,
he told me that we got 16 Institution, and 5 analists through the offering. The Offering will be completed/announced today"
Just spoke to Ed,
he told me that we got 16 Institution, and 5 analists through the offering. The Offering will be completed/announced today
The agent at Lazard Capital told me the offering (4.94 units) had been completed on Thursday. She told me that the over-allotment had not been exercised.
This is slightly at odds with what Ed told you. Also, I do not see the announcement anywhere? Did I miss it or do they plan to issue very late at night, tomorrow or whenever?
European Approval of Vitaros is imminent. It could happen at any moment.
We filed an MAA (marketing Authorization Application) in Europe on April 27, 2011. It was accepted on june 28th. We filed in accordance with the decentralization procedure (DCP) and are using the Netherlands as our reference member state (RMS). Under this procedure we can receive identical commercial marketing approvals from several member states.
Now, why is approval very likely to be announced at any moment? Well, the entire process takes around 240 days. Yes, it can be a bit longer or shorter. Now, let's do the math. The MAA was accepted on June 28th. Now 240 days is approximately 8 months. That puts acceptance in late February, plus or minus a few days. Hence, Vitaros approval in Europe could be announced at any moment.
A European approval of Vitaros could be Dr. Bassam Damaj's surprise Ace-the-hole and the reason institutions gobbled up the 4.94 million units in a nano-second. Cheers.
The pps is clearly heading up.
It should be obvious to everyone that the pps will quickly start to recover and start spiking and trending upward in rather dramatic fashion. Why? A few reasons.
First, and most importantly the immediate purchase of the massive share offering makes it abundantly clear that institutional buyers purchased the 4.94 million plus 740k over-allotment of shares and warrants.
Second, the details of the offer indicate institutional and wealthy investors obviously feel the pps is heading back north of $5.25 per share. Five dollars and twenty-five cents is the strike price of these warrants.
Since there is currently no public market for these warrants their value can only be realized when the pps rockets past $5.25 per share.
I know you are probably saying to yourself, well it is true that there is no current publicly traded market for the warrants but in the coming months if the pps is trading between 4.00-5.00 per share, underwriters on Wall Street will establish a market. True. The market would be thinly traded and subject to wild swings in price, more so than the option's market due to the relatively limited supply of these warrants, only 5 million.
But if you look at the secondary press release Dr. Bassam Damaj states: "There is no public market for these warrants and we do not expect one to develop." Why would he make such a bold statement?
The cynics and sceptics would say, "Of course he is going to say that. He does not want existing shareholders to worry about the buyers of units (share plus a warrant for $4.05) flipping the shares and the warrants for a quick profit. This would certainly be true if the warrant, conservatively valued at $1.20 per warrant, could be sold in a public market. Note: 3.65 for a share + 1.25 for the warrant = $4.90 per unit. Since they paid 4.05 for the unit, they would be making an immediate .85 per unit. Five million units x .85 = $4.25 million in immediate profits. Nobody could pass up that opportunity.
Okay, Dr Damaj might have a incentive to keep the pps from tanking and claim truthfully that there is currently no public market for warrants. However, the second part of the statement "and I do not expect a market to develop." Whoa, that puts him in legal jeopardy. Dr. Damaj knows darn well that a warrant market is extremely likely to develop on Wall Street over the next couple of months. Why would he expose himself and Apricus to such legal jeopardy? There is only one explanation, a market will not develop.
Holy smokes. That is it. A market will not develop. What would prevent a market from developing? What would prevent Wall Street underwriters from buying and selling these warrants? Do you see it now?
The only thing that will prevent a market from developing is an explosive rise in the pps. If the pps explodes past $5.25 existing warrant holders will exercise those warrants. That means they will sell the warrants back to Apricus for $5.25 per share. (Since warrants only allow the purchase of 1/2 share, the exercise price of the warrant = $2.625 per warrant.)
Dr. Damaj has just told existing shareholders, unit holders and shorts in very clear language that good news is coming soon and the pps is going to take off.
There was a time to sell this stock but now is the time to buy with both hands and then buy some more. Cheap shares will not last. Shorts, congratulations on your recent profits. You were right the price did tank. However, your time is done for now. GLTA.
A purchase of 15 percent of outstanding shares triggers the poison pill scenario.
A pps in the 5.50-7.50 range represents around a 100 percent gain. Not bad.